Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer
Qian Zhou, Wensheng Chen, Zhenzhen Fan, Zhipeng Chen, Jinxia Liang, Guandi Zeng, Lu Liu, Wanting Liu, Tong Yang, Xin Cao, Biao Yu, Meng Xu, Ye‐Guang Chen, Liang Chen
Abstract
NSCLC cells deficient of MYOCD are particularly sensitive to TGFBR kinase inhibitor (TGFBRi). TGFBRi and stemness inhibitor synergize with existing drugs to treat MYOCD deficient lung cancers. Our current work shows that loss of function of MYOCD creates Achilles' heels in lung cancer cells, which might be exploited in clinic.
Topics & Concepts
Lung cancerMedicineCancer researchLungNeuroscienceInternal medicinePsychologyCancer-related gene regulationEpigenetics and DNA MethylationPeptidase Inhibition and Analysis